President Donald Trump<\/strong> on Thursday announced new pricing deals with pharmaceutical giants Novo Nordisk<\/strong> and Eli Lilly<\/strong>, lowering the cost of the most in-demand weight-loss medications<\/strong> in the United States.<\/p>\n\n\n\n Under the plan, Novo Nordisk<\/strong> will offer the lowest dose of Wegovy<\/strong> at $149 per month<\/strong>, extending the reduced price across its direct-to-patient programs. The company said it will also cut prices on Ozempic<\/strong> and other injectables through Medicare Part D<\/strong>, Medicaid<\/strong>, and self-pay channels<\/strong>, with additional pricing updates expected in the coming weeks.<\/p>\n\n\n\n Eli Lilly<\/strong> will lower prices on its rival drug Zepbound<\/strong>, offering the lowest dose at $299<\/strong> and higher doses up to $449<\/strong>\u2014around $50 less than current direct-to-patient rates. Its upcoming oral obesity drug Orforglipron<\/strong>, pending FDA approval, will start at $149 per month<\/strong>, with Medicare patients paying no more than $50 per month<\/strong> for either medication.<\/p>\n\n\n\n Trump called the agreements \u201ca triumph for American patients that will save lives and improve the health of millions.\u201d<\/em><\/p>\n\n\n\n Both companies said they are working with the administration under the Most Favored Nation initiative<\/strong>, which seeks to align U.S. drug costs with international prices. They have also launched direct-to-consumer digital platforms<\/strong> to simplify access and cut intermediary costs.<\/p>\n\n\n\n GLP-1 drugs like Wegovy, Ozempic, and Zepbound<\/strong> mimic natural hormones that regulate appetite and blood sugar. Originally designed for diabetes, they have become some of the most sought-after treatments for obesity<\/strong>, though supply shortages and high costs have limited availability.<\/p>\n\n\n\n The price cuts mark a major shift in the pharmaceutical market, potentially expanding access to treatments that have redefined global discussions about weight management and public health.<\/p>\n","protected":false},"excerpt":{"rendered":" The agreements aim to make blockbuster weight-loss drugs like Wegovy, Ozempic, and Zepbound more affordable for millions of Americans. President Donald Trump on Thursday announced new pricing deals with pharmaceutical giants Novo Nordisk and Eli Lilly, lowering the cost of the most in-demand weight-loss medications in the United States. Under the plan, Novo Nordisk will […]<\/p>\n","protected":false},"author":2,"featured_media":2445,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[317,314,313,311,315,318,312,316],"class_list":["post-2444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-u-s","tag-eli-lilly-zepbound","tag-glp-1-drugs","tag-most-favored-nation-plan","tag-novo-nordisk-wegovy","tag-obesity-medication-cost","tag-ozempic-price-cuts","tag-trump-drug-price-deal","tag-trump-health-policy"],"yoast_head":"\n